Andson Biotech logo

ATLANTA, April 30, 2024  –  Andson Biotech , a biotools company developing streamlined sample prep and data analytics solutions for mass spectrometry workflows, has successfully closed a $3.6 million round in equity financing. This capital will support hiring talent to accelerate the market introduction of its inline mass spec sample prep solution,  DynaCHIP . This patented technology seamlessly integrates into existing mass spec workflows, significantly reducing sample prep times. In addition, Andson will deploy funds to develop  DynaMARK , a novel analytics tool that supports emerging cell and gene therapy applications.

“This financing round signifies a significant milestone for  Andson Biotech , demonstrating our commitment to making mass spectrometry more productive for current and next-gen biotherapeutics,”says  CEO and Co-Founder, Mason Chilmonczyk . “We are grateful for the support of investors and advisors who have built successful biotech companies in the past as we embark on this next phase of growth.”

The round was led by  Glenn H. Epstein , an investor with a successful track record in funding and advising multiple companies from early-stage formation to robust sales growth from products and services. He will serve on Andson’s board of directors.

“Andson has made significant technical progress since its inception at  Georgia Tech  in early 2022,” says  Tom O’Brien ,  Executive Chairman  of the board at  Andson Biotech . “Having collaborated closely with the Andson team for the past year, I am confident in their capabilities and vision. More importantly, I am optimistic about the impact Andson’s products will have in the biotools market.”

‍ About Andson Biotech

‍ Headquartered in Atlanta, GA,  Andson Biotech  specializes in providing cutting-edge solutions for mass spectrometry, the gold standard for chemical analysis. At the forefront of its offerings is the  DynaCHIP , a hardware system designed to enhance mass spec workflows, delivering productivity gains of up to 100x.

Andson Biotech’s  initial technology was licensed from  Georgia Tech .  The Company received early financial support from the  Georgia Research Alliance (GRA)  and  Biolocity . Subsequent support from entities like  Y Combinator  (Winter, 2022), the  Merck Digital Sciences Studio  (Inaugural Cohort ‘23), and  BioTools Innovator  (2023 Finalist) have further propelled the company’s growth, bringing its total funding to over $5 million since January 2022.

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: